Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionThe Antibody Response against HIV-1Influenza virus hemagglutinin stalk-based antibodies and vaccinesImpaired antibody response causes persistence of prototypic T cell-contained virusAntibodies against viruses: passive and active immunizationThe good and evil of complement activation in HIV-1 infectionHigh-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samplesFunctional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionPreclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.Post-infection immunodeficiency virus control by neutralizing antibodiesIn vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Presence of IgG anti-gp160/120 antibodies confers higher HIV capture capacity to erythrocytes from HIV-positive individuals.Critical issues in mucosal immunity for HIV-1 vaccine development.Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyComplement and HIV-I infection/HIV-associated neurocognitive disorders.MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDSNeutralizing and other antiviral antibodies in HIV-1 infection and vaccination.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virusGM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.Strategies for eliciting HIV-1 inhibitory antibodiesEffect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedStimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression.Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in transA novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges.Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Effector mechanisms of humoral immunity to porcine reproductive and respiratory syndrome virus.Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.
P2860
Q21245045-0D73BF1A-ED48-461C-B87E-C6DE6CC13ED0Q27000889-48DD6849-E5EB-4DF4-B58F-7F560469C6D6Q27001190-5AB8A38C-3CCE-4542-9FD1-F7C0C3A78739Q27331309-BA3FA9DB-D096-4EF1-806D-ADAC9300632AQ27489392-7AAECAA0-E496-455A-9706-8022BA140A61Q28275986-96607763-1089-44C0-A7F5-D00F01419DABQ28389941-EB945093-350A-4F76-B633-E875BB278E2BQ28743199-F56A3A14-A2AF-41A7-A2C8-381FF685B0A4Q28748901-CC3C7D3A-CEDB-463B-BEE6-931A4E819506Q30374995-3C9E3B4A-5DF6-4F06-B4BC-C9D0E072226DQ33288264-7A28EB9E-75C4-4236-B626-911B634442DBQ33618013-483ADDA1-6B39-46C0-B033-1E48219AE439Q33874253-1544D2E4-6D8E-4D59-AC5A-00B0C982EF7DQ34218827-BF0B8FEE-9B75-4C99-AA1C-4BF35B05D9A4Q34438445-9828C74B-7806-46CA-B811-EB8961831149Q34459985-8DA0BD25-C3FB-41C3-BFAF-DD148591472CQ34485178-4626A14A-667A-45AA-A511-D6D0CBA8CC2EQ34610122-6D634ED6-32C6-4C4F-AB36-B3751F4A4492Q34681455-491827CB-7594-4C34-92F4-303B0A917D8FQ34848486-583678E2-C778-47DD-BE69-78AED7AB7E7BQ35097510-872866BF-9247-44BD-9489-7656A1441159Q35208657-6A93893B-595E-4EE7-841B-4A58A81D6083Q35947769-A319A0AA-08F4-4754-A1A1-2313E73FCD0FQ36098975-CC31A05A-D861-4C28-B38F-58FE91E69F8AQ36127805-8940B218-9D00-4BC1-BD1D-ABC5E8090E69Q36407775-1C9D30BE-DE28-4161-82BB-8C5B81192AFCQ36424125-F87A7887-5912-4190-AFE6-F297CA96F12AQ36452155-BF89F410-D43C-46FC-8D20-DAE932D2A777Q36506821-FBC8EA48-1EAD-45F7-BD94-95AE6BE9DF95Q36540060-1CC5FFA6-487A-490A-A0B9-27083298CBCBQ36568672-73966E59-DEE7-4ABB-8109-DD3BE0B913DDQ36759980-EAD87D42-28F3-488C-8F91-355110E78274Q36845632-31D5EF82-901E-4D14-AF6F-D278C9A8F64CQ36990047-58A88603-7B73-421C-B2BC-6C4A6A3A8EDFQ37121901-30EE8497-72CE-4D71-BE40-C89D8096FA8FQ37268317-7902F440-3418-46D6-A208-08677598FDDCQ37677278-C86D3A82-9D43-4D41-A53A-70409880FEA2Q38717198-EDBE46AF-E981-43BB-A76D-E40199DF7671Q39245066-66485C66-2653-49ED-87D8-CE791BC243A0Q39398170-79ACC300-16F1-4108-8E54-7AD482BEEB4B
P2860
Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Complement lysis activity in a ...... acute phase of HIV-1 infection
@ast
Complement lysis activity in a ...... acute phase of HIV-1 infection
@en
Complement lysis activity in a ...... acute phase of HIV-1 infection
@nl
type
label
Complement lysis activity in a ...... acute phase of HIV-1 infection
@ast
Complement lysis activity in a ...... acute phase of HIV-1 infection
@en
Complement lysis activity in a ...... acute phase of HIV-1 infection
@nl
prefLabel
Complement lysis activity in a ...... acute phase of HIV-1 infection
@ast
Complement lysis activity in a ...... acute phase of HIV-1 infection
@en
Complement lysis activity in a ...... acute phase of HIV-1 infection
@nl
P2093
P2860
P50
P1433
P1476
Complement lysis activity in a ...... acute phase of HIV-1 infection
@en
P2093
Amapola Manrique
Barbara Niederöst
Marek Fischer
Rainer Weber
P2860
P356
10.1371/JOURNAL.PMED.0030441
P407
P577
2006-11-01T00:00:00Z